Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.67), $0.12 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $4.94 million versus the consensus estimate of $3.73 million.

Cash, cash equivalents and marketable securities as of December 31, 2015 were approximately $224 million, compared to $161 million on September 30, 2015. Cash, cash equivalents and marketable securities as of December 31, 2015 included total net proceeds of approximately $73 million from the company's initial public offering of common stock and the underwriters' exercise of their over-allotment option in November 2015.

Based on the company’s current operating plan, Voyager expects to end 2016 with cash, cash equivalents and marketable securities of approximately $160 million and projects that its existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into 2019.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.